Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1645 1648 1671 1672
This examiner grants 57% of resolved cases
Ruixue Wang operates in Art Unit 1632 of Tech Center 1600. The examiner has 114 resolved cases and an allowance rate pct of 57.0. This rate indicates a moderate level of difficulty for applicants.
The interview lift pct of 18.8 suggests that interviews are a useful way to improve the chances of success. This lift provides a meaningful boost over the 57.0% base allowance rate. Practitioners should consider interviews to resolve any outstanding rejections.
The median days to allowance is 1216. This timeline provides a reliable benchmark for the duration of the patenting process. The 114 resolved cases offer a solid statistical foundation for these metrics.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17603302 | MODIFIED AAV VECTORS THAT DAMPEN THE HUMORAL IMMUNE RESPONSE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17934810 | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß CORONAVIRUS ANTIBODY IN A SAMPLE | Final Rejection | Abbott Laboratories |
| 18882219 | Nant COVID Vaccine Cross Reactivity | Non-Final OA | ImmunityBio, Inc. |
| 18835550 | PRODUCTION METHOD FOR INDUCED PLURIPOTENT STEM CELLS | Non-Final OA | KANEKA CORPORATION |
| 18560338 | METHODS AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE BY A RECOMBINNAT VACCINIA VIRUS | Final Rejection | UNIVERSITY OF ROCHESTER |
| 17055502 | IN SITU CELL SCREENING METHODS AND SYSTEMS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18701901 | Neutralizing Trivalent Protein-DNA Molecules (TRI-PDBODY) for SARS-COV-2 Infection Treatment | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18496026 | ENGINEERED LIPOSOMES FOR NEUTRALIZATION OF SARS-COV-2 AND OTHER ENVELOPED VIRUSES | Non-Final OA | Vanderbilt University |
| 18704248 | ONCOLYTIC VIROTHERAPY COMPOSITIONS AND METHODS | Non-Final OA | UNM RAINFOREST INNOVATIONS |
| 17670091 | PRIMER DESIGN AND USE FOR LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) PATHOGEN DETECTION | Final Rejection | Purdue Research Foundation |
| 17996797 | LIPID NANOPILLAR ARRAY-BASED IMMUNOASSAY | Non-Final OA | KOREA INSTITUTE OF MACHINERY & MATERIALS |
| 16975541 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFOR | Final Rejection | The Trustees of the University of Pennsylvania |
| 17998592 | STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 18458108 | EPSTEIN BARR VIRUS VACCINES | Non-Final OA | Fred Hutchinson Cancer Center |
| 17996287 | IDENTIFICATION OF NSP1 GENE AS TARGET OF SARS-COV-2 REAL-TIME RT-PCR USING NANOPORE WHOLE GENOME SEQUENCING | Final Rejection | The University of Hong Kong |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | Non-Final OA | The University of Hong Kong |
| 17905040 | METHOD FOR PRODUCING INACTIVATED INFLUENZA VACCINE AND VACCINE COMPOSITION THEREOF | Non-Final OA | DENKA COMPANY LIMITED |
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18564987 | METHODS AND COMPOSITIONS FOR TRANSDUCTION OF NK CELLS | Final Rejection | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18711088 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS | Non-Final OA | CITY OF HOPE |
| 18566962 | ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS AND USE THEREOF | Non-Final OA | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | Non-Final OA | BIONOXX INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy